360 related articles for article (PubMed ID: 32477121)
41. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
42. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
43. Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin.
Smith ML
Breast Cancer Res Treat; 1999 Nov; 58(2):99-105. PubMed ID: 10674873
[TBL] [Abstract][Full Text] [Related]
44. Targeting MDM2-p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach.
Ghafoor NA; Yildiz A
ACS Omega; 2023 Sep; 8(38):34583-34596. PubMed ID: 37779953
[TBL] [Abstract][Full Text] [Related]
45. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
46. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen CY; Oliner JD; Zhan Q; Fornace AJ; Vogelstein B; Kastan MB
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2684-8. PubMed ID: 8146175
[TBL] [Abstract][Full Text] [Related]
47. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.
Maya R; Balass M; Kim ST; Shkedy D; Leal JF; Shifman O; Moas M; Buschmann T; Ronai Z; Shiloh Y; Kastan MB; Katzir E; Oren M
Genes Dev; 2001 May; 15(9):1067-77. PubMed ID: 11331603
[TBL] [Abstract][Full Text] [Related]
48. P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.
Trino S; De Luca L; Laurenzana I; Caivano A; Del Vecchio L; Martinelli G; Musto P
Front Pharmacol; 2016; 7():491. PubMed ID: 28018226
[TBL] [Abstract][Full Text] [Related]
49. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.
Qin JJ; Wang W; Zhang R
Prog Mol Biol Transl Sci; 2017; 151():195-216. PubMed ID: 29096894
[TBL] [Abstract][Full Text] [Related]
50. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
[TBL] [Abstract][Full Text] [Related]
51. Mdm2 promotes the rapid degradation of p53.
Haupt Y; Maya R; Kazaz A; Oren M
Nature; 1997 May; 387(6630):296-9. PubMed ID: 9153395
[TBL] [Abstract][Full Text] [Related]
52. Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
Qi SM; Cheng G; Cheng XD; Xu Z; Xu B; Zhang WD; Qin JJ
Front Cell Dev Biol; 2020; 8():233. PubMed ID: 32300595
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
54. A high-throughput screen measuring ubiquitination of p53 by human mdm2.
Murray MF; Jurewicz AJ; Martin JD; Ho TF; Zhang H; Johanson KO; Kirkpatrick RB; Ma J; Lor LA; Thrall SH; Schwartz B
J Biomol Screen; 2007 Dec; 12(8):1050-8. PubMed ID: 17989425
[TBL] [Abstract][Full Text] [Related]
55. The MDM2-p53 pathway revisited.
Nag S; Qin J; Srivenugopal KS; Wang M; Zhang R
J Biomed Res; 2013 Jul; 27(4):254-71. PubMed ID: 23885265
[TBL] [Abstract][Full Text] [Related]
56. Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase.
Giono LE; Resnick-Silverman L; Carvajal LA; St Clair S; Manfredi JJ
Oncogene; 2017 Dec; 36(49):6762-6773. PubMed ID: 28806397
[TBL] [Abstract][Full Text] [Related]
57. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.
Di Cintio A; Di Gennaro E; Budillon A
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):1-13. PubMed ID: 19663772
[TBL] [Abstract][Full Text] [Related]
58. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
59. Enhanced MDM2 Oncoprotein Expression in Soft Tissue Sarcoma: Several Possible Regulatory Mechanisms.
Pollock RE; Lang A; El-Naggar AK; Radinsky R; Hung MC
Sarcoma; 1997; 1(1):23-9. PubMed ID: 18521197
[TBL] [Abstract][Full Text] [Related]
60. HS-1793 inhibits cell proliferation in lung cancer by interfering with the interaction between p53 and MDM2.
Lim C; Lee PCW; Shim S; Jang SW
Oncol Lett; 2022 Aug; 24(2):290. PubMed ID: 35928802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
